Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
This COVID-19 roundup includes coverage of the combination of amubarvimab and romlusevimab to manage COVID-19 infection, the association between COVID-19 and incident diabetes, and the effectiveness of...
This COVID-19 roundup includes research on an alternative therapy to nirmatrelvir-ritonavir, a vaccine regimen that protects pregnant women and infants against certain variants, pegylated interferon lambda...
Researchers examined the effectiveness of the monoclonal antibody, nirsevimab, in protecting infants from the respiratory syncytial virus (RSV) and RSV lower respiratory tract infection.
This COVID-19 roundup includes coverage of the FDA’s recent approval of bivalent booster vaccines for younger age groups, the use of COVID-19 PrEP and associated risk for the virus, an increase of...
Researchers aimed to establish common symptoms associated with monkeypox virus infection to assist in minimizing the spread of the infection, and bringing awareness to clinicians and the public.
The authors expanded upon research conducted in 2015 by including deaths across different global demographics that did not occur in hospitals. This is the first study to examine the RSV disease burden in...
